MedPath

Cipargamin

Generic Name
Cipargamin
Drug Type
Small Molecule
Chemical Formula
C19H14Cl2FN3O
CAS Number
1193314-23-6
Unique Ingredient Identifier
Z7Q4FWA04P
Background

Cipargamin has been used in trials studying the treatment of Malaria, Cure Rate, and Plasmodium Falciparum Malaria.

Clinical Trials
Related News

To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria

Phase 2
Recruiting
Conditions
Severe Malaria
Interventions
First Posted Date
2020-12-19
Last Posted Date
2025-03-28
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
252
Registration Number
NCT04675931
Locations
🇺🇬

Novartis Investigative Site, Tororo, Uganda

Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects

Phase 1
Completed
Conditions
Malaria
Interventions
Drug: Placebo
First Posted Date
2020-03-25
Last Posted Date
2021-12-13
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
57
Registration Number
NCT04321252
Locations
🇧🇪

Novartis Investigative Site, Antwerpen, Belgium

Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.

Phase 2
Completed
Conditions
Malaria
Interventions
First Posted Date
2017-11-07
Last Posted Date
2021-10-11
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
188
Registration Number
NCT03334747
Locations
🇺🇬

Novartis Investigative Site, Tororo, Uganda

Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos

Phase 1
Terminated
Conditions
Plasmodium Falciparum Malaria
Interventions
First Posted Date
2015-09-07
Last Posted Date
2019-07-23
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
8
Registration Number
NCT02543086
Locations
🇦🇺

Novartis Investigative Site, Brisbane, Queensland, Australia

A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infection

Phase 2
Completed
Conditions
Cure Rate
Interventions
First Posted Date
2013-05-23
Last Posted Date
2015-09-10
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
11
Registration Number
NCT01860989
Locations
🇻🇳

Novartis Investigative Site, Hanoi, Vietnam

A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection

Phase 2
Completed
Conditions
Malaria
Interventions
First Posted Date
2013-04-19
Last Posted Date
2016-10-31
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
25
Registration Number
NCT01836458
Locations
🇻🇳

Novartis Investigative Site, Ho Chi Minh, Vietnam

Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection

Phase 2
Completed
Conditions
Malaria
Interventions
First Posted Date
2012-02-01
Last Posted Date
2013-05-13
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
27
Registration Number
NCT01524341
Locations
🇹🇭

Novartis Investigative Site, Tak, Thailand

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy